Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

Solange Peters(University of Lausanne), Rolf A. Stahel(University Hospital of Zurich), Lukas Bubendorf(University Hospital of Basel), Philip Bonomi(Rush University Medical Center), Augusto Villegas(Florida Cancer Specialists & Research Institute), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Christina S. Baik(Seattle Cancer Care Alliance), Dolores Isla(Hospital Clínico Universitario Lozano Blesa), Javier de Castro(Hospital Universitario La Paz), Pilar Garrido(Hospital Universitario Ramón y Cajal), Achim Rittmeyer(Institut für Lungenforschung), Marcello Tiseo(Ospedale di Parma), Christoph Meyenberg(Roche (Switzerland)), Sanne de Haas(Roche (Switzerland)), Lisa H. Lam(Gene Therapy Laboratory), Michael W. Lu(Gene Therapy Laboratory), Thomas E. Stinchcombe(Duke University)
Clinical Cancer Research
September 11, 2018
Cited by 230Open Access
Full Text

Abstract

Abstract Purpose: HER2-targeted therapy is not standard of care for HER2-positive non–small cell lung cancer (NSCLC). This phase II study investigated efficacy and safety of the HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with previously treated advanced HER2-overexpressing NSCLC. Patients and Methods: Eligible patients had HER2-overexpressing NSCLC (centrally tested IHC) and received previous platinum-based chemotherapy and targeted therapy in the case of EGFR mutation or ALK gene rearrangement. Patients were divided into cohorts based on HER2 IHC (2+, 3+). All patients received T-DM1 3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was investigator-determined overall response rate (ORR) using RECIST v1.1. Results: Forty-nine patients received T-DM1 (29 IHC 2+, 20 IHC 3+). No treatment responses were observed in the IHC 2+ cohort. Four partial responses were observed in the IHC 3+ cohort (ORR, 20%; 95% confidence interval, 5.7%–43.7%). Clinical benefit rates were 7% and 30% in the IHC 2+ and 3+ cohorts, respectively. Response duration for the responders was 2.9, 7.3, 8.3, and 10.8 months. Median progression-free survival and overall survival were similar between cohorts. Three of 4 responders had HER2 gene amplification. No new safety signals were observed. Conclusions: T-DM1 showed a signal of activity in patients with HER2-overexpressing (IHC 3+) advanced NSCLC. Additional investigation into HER2 pathway alterations is needed to refine the target population for T-DM1 in NSCLC; however, HER2 IHC as a single parameter was an insufficient predictive biomarker.


Related Papers

No related papers found

Powered by citation graph analysis